A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus.
Kalunian KC, Furie R, Morand EF, Bruce IN, Manzi S, Tanaka Y, Winthrop K, Hupka I, Zhang LJ, Werther S, Abreu G, Hultquist M, Tummala R, Lindholm C, Al-Mossawi H.
Arthritis Rheumatol. 2023 Feb;75(2):253-265. doi: 10.1002/art.42392. Epub 2022 Nov 11.
PMID:36369793
Management of systemic lupus erythematosus: a systematic literature review informing the 2023 update of the EULAR recommendations.
Kostopoulou M, Mukhtyar CB, Bertsias G, Boumpas DT, Fanouriakis A.
Ann Rheum Dis. 2024 Oct 21;83(11):1489-1501. doi: 10.1136/ard-2023-225319.
PMID:38777375
Severe pneumonia in Chinese patients with systemic lupus erythematosus.
Peng L, Wang Y, Zhao L, Chen T, Huang A.
Lupus. 2020 Jun;29(7):735-742. doi: 10.1177/0961203320922609. Epub 2020 May 13.
PMID:32403979
Blood transcriptome analysis revealed the crosstalk between severe COVID-19 and systemic lupus erythematosus.
Meng R, Zhang N, Yang F, Xu Z, Wu Z, Du Y.
J Infect. 2023 Apr;86(4):e104-e106. doi: 10.1016/j.jinf.2023.02.011. Epub 2023 Feb 10.
PMID:36775249
Systemic lupus erythematosus presenting as non-resolving pneumonia: a case report.
Stappers S, van der Graaff D, Hoffman I, Moorkens W, Hantson I, Stappaerts I, Nowé V, Vervliet L.